RQ-00000010

Phase 1Small molecule

VVirginia Commonwealth University

RQ-00000010 is one of 47 small molecule programs targeting Gastroparesis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroparesisActive, not recruiting

GastroparesisPhase 1

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Gastroparesis

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

1 2

Zelnorm

AAlfasigma S.p.A.

Approved

1 3

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

1 4

Haldol

DDePuy Orthopaedics

Approved

1 5

Relistor

SSalix

Approved

—6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Pitocin

Resotran

2 9

Mosapride

SSeoul National University Hospital

Approved

1 10

Nereus

VVanda Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroparesis1 trial

RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease

Completed·VVirginia Commonwealth University·Phase 1·NCT02838797·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RQ-00000010. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RQ-00000010 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RQ-00000010. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Virginia Commonwealth University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVirginia Commonwealth University

RQ-00000010

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroparesis1 trial

References

Drug Info

Quick Facts

Related News